Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 5/20 | 0.37 |
| ▸ | ACHE | P22303 | 4/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | MARK4 | Q96L34 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065739 | 0.77 | KYNU (0.50) | AOC3KDM4ELMNA | |
| SCHEMBL5069157 | 0.77 | AOC3 (0.51) | AOC3L3MBTL1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL1527256 | 0.77 | AOC3 (0.51) | AOC3L3MBTL1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL5069152 | 0.77 | AOC3 (0.51) | AOC3L3MBTL1KDM4ELMNASMN1; SMN2 | |
| SCHEMBL168175 | 0.74 | PNMT (0.54) | L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL4596308 | 0.71 | ACHE (0.38) | L3MBTL1ALDH1A1BCHEACHE | |
| SCHEMBL5065117 | 0.71 | SMN1; SMN2 (0.44) | L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL14860359 | 0.71 | AOC3 (0.48) | AOC3L3MBTL1LMNASMN1; SMN2 | |
| SCHEMBL5065719 | 0.70 | CYP51A1 (0.39) | AOC3L3MBTL1KDM4EALDH1A1LMNA | |
| SCHEMBL8647625 | 0.69 | TAAR1 (0.42) | AOC3L3MBTL1KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | HEERDING DIRK A | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318947-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | AOC3 4778/4885L3MBTL1 1699/4885KDM4E 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.